Background. Centers for Disease Control and Prevention guidelines recommend caution in prescribing opioids for chronic pain. The characteristics of opioid prescription (OpRx) among kidney transplant (KTx) recipients have not been described in a national population. Methods. We assessed OpRx prevalence among prevalent KTx recipients, and associated duration (long-term, defined as ≥90 days in a year) and dosing (in morphine milligram equivalents per day of <50, 50-89, and ≥90) with outcomes, death and graft loss, among incident KTx recipients using 2006-2010 US Renal Data System files, including Medicare Part D for medication ascertainment. Cox models controlled for recipient factors. Results. Of 36,486 KTx recipients in the 2010 prevalent cohort, approximately 14.6% had long-term OpRx. The strongest association with long-term OpRx after KTx was longterm OpRx before KTx (64%; adjusted odds ratio, 95% confidence interval, 95.2, 74.2-122.1). Incident KTx recipients with longterm OpRx had increased risk of mortality and graft loss compared with those without OpRx or short-term OpRx after KTx. This risk was highest among recipients with long-term OpRx doses of ≥90 morphine milligram equivalents or higher per day (adjusted hazard ratio, 95% confidence interval, 1.61, 1.24-2.10 for death, and 1.33, 1.05-1.67 for graft loss, respectively). Conclusions. In contrast to either no or short-term OpRx, long-term, and especially long-term high-dose OpRx, is associated with increased risk of death and graft loss in US KTx recipients. Causal relationships cannot be inferred, and OpRx may be an illness marker. Nevertheless, efforts to treat pain effectively in KTx recipients with less toxic interventions and decrease OpRx deserve consideration.
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A substantial literature exists on use of opioid prescriptions in the pretransplantation period for both liver and kidney transplants and among kidney donors. [1] [2] [3] [4] More than a quarter of kidney transplant recipients filled a narcotic prescription in the year before transplantation. 3 The highest quartile (≥23.8 mg/kg) of narcotic use before transplantation was associated with increased morbid outcomes after transplantation. The prevalence, predictors, and prognosis of opioid prescriptions after transplantation have not been reported in a national population. Longterm opioid prescription (generally defined as ≥90 days in a calendar year 5 ) is not considered appropriate, particularly for noncancer pain for which a comprehensive benefit to harm evaluation is recommended. 6 We showed opioid medication prescriptions are more common among dialysis patients than the general Medicare population, and long-term opioid prescriptions are associated with increased risk of mortality, termination of dialysis, and hospitalizations in a dose-related manner. 7 A single-center report 8 indicated 11.4% of 1045 kidney transplant recipients from 2004 to 2008 continued to receive outpatient prescription of opioid analgesics during the year after kidney transplantation, mostly for nonsurgery-related pain. Continued prescription of opioids was associated with more frequent hospitalization, but not with acute rejection rates or overall mortality. The authors concluded continued opioid prescription in this setting was not associated with mortality or other adverse outcomes, based on small sample size and relatively brief follow-up.
We assessed the prevalence and duration of opioid medication prescriptions in US kidney transplant recipients, factors associated with prescription, and determined associations between dose of such prescription and mortality and graft loss, using the most recently available data from the United States Renal Data System and the Centers for Medicare & Medicaid Services (CMS), including Medicare Part D files for prescription information.
MATERIALS AND METHODS
Study Design, Data Sources, and Sample Selection Using standard analysis files from the United States Renal Data System, a national end-stage renal disease (ESRD) registry, we performed a retrospective cohort study to (1) describe trends in the proportion of prevalent transplant recipients who received long-term opioid medication prescriptions, overall and for specific opioids, from 2006 to 2010, (2) examine factors associated with long-term opioid medication prescriptions in 2010 prevalent transplant recipients, and (3) examine associations of all-cause death and of graft loss with dose of filled long-term opioid prescriptions in recipients having a first transplant in [2007] [2008] [2009] .
Two sets of cohorts (prevalent transplant cohorts for the first and second objectives, and an incident transplant cohort for the third) were identified. We identified annual cohorts of adult recipients 20 years or older, who resided in one of the 50 states or Washington, DC, and were not under hospice care (identified through claims with the place of service listed as hospice) in 2006-2010. To ensure complete claims data for recipients, the cohorts were further limited to recipients with a full-year functioning graft, who had Medicare as their primary payer and full Part A, B, and D coverage in each study year. The selection of transplant recipients in year 2010 is illustrated ( Figure 1 ). Based on the same criteria, all living and eligible recipients with a functioning transplant from January 1 to December 31 in each calendar year were included in the remaining annual cohorts for 2006-2009. For the third objective, we identified adult recipients of a first kidney transplant in 2007-2009 who were not under hospice care and resided in one of the 50 states or Washington, DC. To ensure complete claims data to define recipients' status of filled opioid prescriptions after transplantation, the cohort was further limited to recipients with full and continuous Part A, B, and D coverage for whom Medicare was the primary payer from the date of transplantation until the date of death or day 365 after transplantation, whichever came first. The selection of the incident cohort is illustrated in Figure 2 .
Study Measures
For each recipient, Part D prescription claims data were used to determine whether a recipient had ever filled an opioid medication prescription (Table S1 , SDC, http://links. lww.com/TP/B515), and the days' supply for each prescription obtained from an outpatient pharmacy during a given calendar year or in a specified observation period.
For the prevalent cohorts, the total days' supply per year is the sum of the days' supply for all the recipient's opioid prescriptions during the year, whether or not the dates of the prescriptions overlapped or continued. We identified a recipient as having a long-term opioid prescription if the recipient's total supply for a study year was 90 days or longer, as having a short-term opioid prescription if the total supply for the year was 1 to 89 days, and as having no prescription if the total days' supply for the year was zero, consistent with previous definitions of chronicity. 5 For the incident cohort, we identified recipients with no, short-term, or long-term opioid prescriptions before transplantation among recipients with continuous Part D coverage for at least 1 year before transplantation. For recipients' opioid prescriptions after transplantation, we identified the date of the 90th cumulative day with a filled opioid prescription as the date of long-term opioid prescription and calculated the morphine milligram equivalent (MME) dosage for each opioid prescription using established conversion tables. 9, 10 We considered overlapping opioid prescriptions per day and calculated a daily MME from the total MME for all opioid prescriptions filled from the first through the 90th cumulative day within 1 year after transplantation divided by 90. We did not have information regarding the indication for which an opioid was prescribed.
Medicare inpatient billing data were used to identify (1) recipients' diagnosis of cancer, (2) whether they had at least 1 pain-related or 1 mental health-related hospitalization, and (3) the number of hospitalizations in each calendar year. Indicator variables were set for recipients with at least 1 hospitalization for cancer, at least 1 hospitalization with a pain diagnosis, and at least 1 hospitalization with a mental health diagnosis (Tables S2 and S3 , SDC, http://links.lww.com/TP/ B515). In addition to inpatient claims, recipients' cancer status was also identified using the CMS Medical Evidence Form (CMS-2728). Recipients' date of cancer diagnosis was assigned as the first hospitalization with a cancer diagnosis or, for recipients identified as having cancer by CMS-2728, the date of ESRD initiation, whichever came first. Recipients' total number of hospitalizations in each study year was counted (1-2, 3-4, or 5 or more hospital admissions).
Medicare physician/supplier billing data were used to indicate whether a recipient resided in a nursing home, identified by at least one claim with the place of service listed as nursing home.
We assigned recipients dual status if they were eligible for insurance coverage by both Medicare and Medicaid in Medicare Part A, B, or D for at least 1 month in each study year. 7, 11 Recipient characteristics were taken from the CMS-2728 and from information collected by the Organ Procurement and Transplantation Network, including self-reported sex, race (white or nonwhite), education (high school or less, some college, or higher), employment and smoking status, as well as comorbid conditions. 7, 12 Age of recipients was calculated as of January 1 of each relevant year or at the date of transplantation (20-44, 45-64, or 65 or older). Based on the year of the first transplantation, recipients' kidney transplant vintage for each year was assigned. 13 For the incident cohort, based on the date of ESRD initiation, recipients' ESRD vintage on the date of the first transplantation was also assigned. We dichotomized type of residential area into rural area and other by using the National Center for Health Statistics Urban-Rural Classification Scheme for counties.
14 Each recipient was assigned a median household income (<$45,000, $45,000-$74,999, or ≥$75,000) based on residential ZIP code, using the 2007-2011 US Census American Community Survey 5-year estimates. 15 
Outcomes
Outcomes of interest for the incident transplant cohort were all-cause graft loss and death. Recipients were followed from the date of transplantation for all-cause graft loss and censored on December 31, 2013. All-cause graft loss included retransplantation, return to regular dialysis, and death. Recipients were also followed for all-cause death and censored on December 31, 2013. The death outcome was not censored at graft loss, and it included deaths that occurred after retransplantation or return to dialysis.
Statistical Analysis
Baseline characteristics of the cohorts were summarized using descriptive statistics and reported as percentages or mean(SD). We calculated annual percentage distributions for age group, sex, race, education, employment status, income, dual status, residential area, transplant vintage, nursing home residence, cancer status, pain-related hospitalization, mental health-related hospitalization, and number of hospitalizations in the 2006-2010 prevalent transplant cohorts. The annual proportion of transplant recipients with long-term opioid prescriptions, overall and for specific opioids, during 2006-2010 was also determined.
Logistic regression models were used to identify factors associated with long-term prescription of any opioid medication in the 2010 prevalent transplant cohort and factors associated with long-term opioid prescription after transplantation in the incident cohort. Cox regression models were specified to assess associations of time to all-cause death and time to graft loss, separately, with dose of filled long-term opioid prescriptions, accounting for changes in the status with dosage of long-term opioid prescriptions during follow-up. The mean MME for the first through 90th cumulative filled days of opioid prescriptions after transplantation was used to indicate the dose of the prescription from the date of the long-term opioid prescription through the end of follow-up. All recipient-level demographic characteristics, ZIP code level median income, medical conditions, and if a new cancer occurred after transplantation (as a time-dependent covariate) were included in multivariate-adjusted Cox models. Sensitivity analyses that limited follow-up to December 31 of 2010, 2011, and 2012 were performed. Statistical significance was defined as P < 0.05 using 2-tailed tests. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC). Table 1 shows the annual cohorts of adult transplant recipients with continuous functioning grafts and who were continuously enrolled in Medicare Part A, B, and D in a specific year, by selected characteristics. There were approximately 21 000 to 36 500 transplant recipients each year during 2006-2010.
RESULTS
The prevalent cohort (n = 36 486 in 2010; Figure 1 ) was different from the parent ESRD transplant population (n = 186 438) in that it had proportionally more women, black recipients, recipients with a greater number of hospitalizations in 2010, and older recipients (data not shown). The study population was predominantly male and white, consistent with the Medicare ESRD transplant population. Approximately 10% lived in neighborhoods with ZIP code median household incomes$75,000 or higher, more than 45% in neighborhoods with incomes less than $45,000, and fewer than 45% in neighborhoods with incomes $45,000 to $74,999. Approximately 60% were dual eligible for Medicare and Medicaid, reflecting the fact that all dual coverage beneficiaries receive Part D coverage, whereas it was optional for other recipients. More than half had transplant vintage greater than 5 years. Approximately 35% had one or more hospital admissions, 2% were nursing home residents, and 20% lived in rural areas. Information on education level was unavailable for approximately30% of the study population. Information on employment status was unavailable for more than 15%. However, among those for whom information was available, approximately35% had some college or higher and 25% were employed (Table 1) (Figure 3) . Highest opioid prescription rates were among women, recipients 45 to 64 years old, recipients living in poorer neighborhoods or rural areas, and nursing home residents. Dual eligible status and unemployment were also associated with higher rates of long-term opioid prescription. Both pain-related and mental health-related hospitalizations were associated with higher long-term opioid prescriptions as were a greater number of hospitalizations.
The opioids most commonly prescribed for 90 days or more during 2006-2010 were hydrocodone (increasing (Table 3) . 
admissions).
In the incident cohort (Figure 2 ), the mean (SD) age of the 14,393 transplant recipients was 50.8(14.0) years and 60.5% were men (Table 5 ). In the 365 days before transplantation, 4618 recipients (32.1%) had no opioid prescriptions, 4720 (32.8%) had opioid prescriptions for less than 90 cumulative days and 1641 (11.4%) had 90 days or more of filled opioid prescriptions. Data on filled prescriptions for the 1 year before transplantation were not available in 23.7% of recipients.
Up to the date of death or day 365 after transplantation, whichever came first, 2432 recipients (16.9%) did not have an opioid prescription and 1644 (11.4%) had 90 or more cumulative days of filled opioid prescriptions. Among the remaining 10,317 recipients (71.7%) having less than 90 cumulative days, 64.0% had 1 to 14, 18.8% had 15 to 30, 12.1% had 31 to 60, and 5.2% had 61 to 89 cumulative days of filled opioid prescriptions. Among 1644 recipients having long-term opioid prescriptions, 62.2% had less than 50 MME per day, 21.8% had 50 to 89 MME per day, and 16.0% had 90 MME or more per day. Percentages did not substantially differ when patients with preexisting cancer or cancer after transplantation were excluded (data not shown).
Among 1641 recipients having long-term opioid prescriptions before transplantation, 64.1% had long-term opioid prescriptions after transplantation. In contrast, only 1.7% of the 4618 recipients without opioid prescription and 6.4% of the 4720 recipients with short-term opioid prescriptions before transplantation had long-term opioid prescriptions after transplantation (P < 0.001; data not shown). Table 5 also shows factors associated with long-term opioid prescriptions after transplantation. Long-term opioid prescription before transplantation was the overwhelmingly dominant factor (adjusted OR of 95.2) for a long-term opioid prescription after transplantation.
During a median 1894 days of follow-up for all-cause death (interquartile range, 1609-2217) after transplantation, 2495 deaths occurred. In the Cox regression model analyzing dosage of long-term opioid prescriptions as a time-varying covariate with no and short-term opioid prescriptions as the referent, the adjusted hazard ratios of death were 1.24 (95% CI, 1.05-1.46) for recipients having less than 50 MME per day, 1.45 (1.15-1.84) for those having 50 to 89 MME per day, and 1.61 (1.24-2.10) for those having 90 MME or more per day. Similarly, during a median 1800 days of follow-up for graft loss (interquartile range, 1490-2149) after transplantation, 4150 graft losses occurred. The adjusted hazard ratios of graft loss were 1.06 (CI, 0.92-1.22) for recipients having less than 50 MME per day, 1.27 (1.03-1.56) for 50 to 89 MME per day, and 1.33 (1.05-1.67) for 90 or more MME per day (Table 6 ). Findings from sensitivity analyses that limited follow-up duration were similar to those from the primary analysis (data not shown). Percent of transplant recipients who had a prescription for ≥90 days of a specific opioid, by year 
DISCUSSION
Approximately 14% of prevalent US kidney transplant recipients had opioid prescriptions for 90 days or more each year. Eleven percent of incident recipients had long-term opioid prescriptions after transplantation. Of those, almost 22% were prescribed a daily dose of 50 to 89 MME, which the Centers for Disease Control and Prevention (CDC) indicate is associated with increased risk of overdose. Sixteen percent had a dose of 90 or more MME, which the CDC recommends should be avoided. 16 The overwhelming risk factor for long-term opioid prescriptions after transplantation was receipt of long-term opioid prescriptions before transplantation (64%, and an OR of 95) compared to recipients who were not prescribed opioid medications (1.7%) or had short-term opioid prescriptions before transplantation (6.4%), consistent with reports of an enduring impact of initial opioid prescriptions. 17, 18 After transplantation, compared to no or short-term prescription, long-term prescription was associated with an increased risk of death and graft loss. The magnitude of all associations increased sequentially with higher (≥90 MME) compared to lower doses of long-term opioid prescriptions. Using the same definition, long-term prescription of opioids increased in the general Medicare population, from 4.6% in 2007 to 7.4% in 2012. 5 We also found that only 5 states accounted for more than 20% of prescriptions of long-term opioids among transplant recipients, consistent with geographic concentration reported by the CDC and others. 19 Whereas the largest single-center study of opioid use after transplantation found most opioids were prescribed for nonsurgical musculoskeletal pain, 8 in a cross-sectional comparative study in 164 hemodialysis patients and 114 stable deceased donor kidney transplant recipients using the modified McGill Pain Questionnaire, 20 more than 60% of both hemodialysis patients and kidney transplant recipients reported pain.
Transplant recipients have specific, if not unique etiologies of pain, including calcineurin inhibitor-associated pain 21, 22 and avascular necrosis of bone. 23, 24 Whereas neither are reportedly common, long-term opioid therapy does not represent optimal or even appropriate therapy in either case.
The CDC recently released clinical guidelines for opioid prescription, 25 including checklists for provider prescription. Transplant recipients were not specifically addressed and were not explicitly considered as a group at greater risk of harm, although recipients with renal insufficiency were included in this category. The lowest dose and duration of opioid treatment is recommended, and nonopioid approaches are considered essential. This last point is critical because many previous assessments of pain control, including in the ESRD population, primarily considered analgesic and opioid drug prescriptions as appropriate treatment for pain, and gave less emphasis to nonpharmacologic therapies, such as cognitive behavioral therapy (CBT), psychotherapy, and biofeedback techniques. [26] [27] [28] This is a crucial shortcoming given our finding that longterm opioid prescription before transplantation is a predictor of long-term opioid prescription after transplantation, which is associated with adverse outcomes. Current guidelines for transplant screening do not make management recommendations for candidates with long-term opioid use. At a minimum, given the conflicting findings of causes of transplantationrelated pain, the etiology and management of such pain among transplant candidates should be an urgent topic of investigation. In contrast to the general population, where CBT has been assessed and found effective for pain management in clinical trials, 29, 30 no reports of its efficacy have been published among transplant recipients. 31 In addition, transplant candidates and recipients with pain should be assessed for the presence of coexisting diagnoses, such as depression, anxiety, and sleep disorders, since pain is often linked to these conditions. [32] [33] [34] Perception of pain can be intensified by depression and anxiety, both of which occur frequently in the ESRD population. 26, [31] [32] [33] These may be responsive to both pharmacologic and nonpharmacologic therapies, such as antidepressants or CBT, which may not be considered typical interventions for pain. Treatment addressing these conditions may ameliorate perceived pain. In addition to research using buprenorphine and naloxone, 35, 36 newer therapies for patients using opioid medications are being developed. Retrospective analysis does not allow distinction between whether these medications are prescribed in candidates or recipients at high risk of death, with terminal conditions, or whether these medications may causally contribute to their increased risk of death. Pain itself, rather than or in addition to the prescription of medication, may be in the causal pathway of mortality. 38 However, the strong link between opioid prescription before and after transplantation argues against opioid prescription in terminal or severely morbid conditions, since such patients would presumably be much less likely to undergo transplantation.
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Our study was limited to those recipients with full Medicare Part A, B and D coverage. To the extent that prescription rates and outcomes are different in the remaining transplant population, our results may not be fully applicable to the universe of transplant recipients. Only filled prescriptions, and not actual prescription or consumption of opioids were assessed in this study. The observational and retrospective nature of this analysis establishes associations only, not causation. Findings of increased risk of death and graft loss among recipients prescribed opioids could be related to their prescription in recipients with preexisting higher risk of mortality or those who already had progressive allograft failure, although these associations persisted despite adjustment for comorbid conditions and other factors known to be associated with mortality. We do not know the cause of death or graft loss in the recipients in this study.
In summary, we report a high rate of long-term opioid prescription in the prevalent kidney transplant population. Long-term opioid prescriptions are associated with increased risk of mortality and graft loss, although a causal role cannot be established.
A "transplant-specific" interpretation of CDC guidelines for opioid use could include an initial discussion with the candidate or recipient with a similar level of detail given to immunosuppressive medications. The findings that providers usually continue pretransplant prescriptions of long-term, high-dose opioids after transplantation should prompt a reemphasis on evaluating all medication use, including opioids, at the candidate's transplant evaluation. To the extent that opioid drugs may cause death in transplant recipients, appropriate clinical interventions to reduce drug prescription and dose level, and offer nonpharmacologic options, while keeping in mind recipient satisfaction and comfort, are warranted. The impact of long-term opioid prescription on other aspects of transplant recipient care, such as quality of life, immunosuppressive medication adherence, or adherence generally, is unknown and is a worthy subject of further investigation. Nonpharmacologic therapies for pain control, and approaches that minimize drug doses and duration of therapy deserve further study in this population, as they may result in lower recipient mortality and morbidity. None-opioid prescription, 0 days filled opioid prescription; short-term opioid prescription, 1-89 days filled opioid prescription; long-term opioid prescription, 90 days or more filled opioid prescription. HR, hazard ratio; CI, confidence interval; MME, morphine milligram equivalent; AIDS, acquired immunodeficiency syndrome.
